The Pfizer-BioNTech Covid-19 vaccine appears to be safe in people previously diagnosed with myocarditis, according to a small study presented Thursday at a European medical conference.
Pfizer and BioNTech are expected to seek U.S. authorization this week for a second Covid-19 vaccine booster for people 65 and older, according to a person familiar with the plans.
Nearly half of all European countries have recorded increases in new Covid-19 cases in the past week, according to an NBC News analysis of data from the Johns Hopkins Coronavirus Resource Center.
Newly emerging data suggest the Pfizer-BioNTech Covid vaccine works substantially less well at preventing infection and hospitalizations in children aged 5 to 11 than it does in those aged 12 to 17 — a finding that is raising questions about whether the companies chose the wrong dose for the younger children.
/cloudfront-us-east-2.images.arcpublishing.com/reuters/PL5C564OSZP7RA45K7JBH2FYYQ.jpg)
/cloudfront-us-east-2.images.arcpublishing.com/reuters/Y2Y72ETNQBOFRNI4C2T7J2TTZA.jpg)
/cloudfront-us-east-2.images.arcpublishing.com/reuters/HKUXRIWX7VJJPJZVABZNE653NU.jpg)
